Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Quince Therapeutics stock price, quote, forecast and news

QNCX
US22053A1079
A2PHHD

Price

0.70
Today +/-
+0.00
Today %
+0.24 %
P

Quince Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Quince Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Quince Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Quince Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Quince Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Quince Therapeutics Stock Price History

DateQuince Therapeutics Price
9/6/20240.70 undefined
9/5/20240.70 undefined
9/4/20240.70 undefined
9/3/20240.69 undefined
8/30/20240.69 undefined
8/29/20240.69 undefined
8/28/20240.66 undefined
8/27/20240.69 undefined
8/26/20240.67 undefined
8/23/20240.66 undefined
8/22/20240.64 undefined
8/21/20240.64 undefined
8/20/20240.61 undefined
8/19/20240.61 undefined
8/16/20240.55 undefined
8/15/20240.54 undefined
8/14/20240.55 undefined
8/13/20240.58 undefined
8/12/20240.69 undefined

Quince Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Quince Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Quince Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Quince Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Quince Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Quince Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Quince Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Quince Therapeutics’s growth potential.

Quince Therapeutics Revenue, EBIT and net profit per share

DateQuince Therapeutics RevenueQuince Therapeutics EBITQuince Therapeutics Net Income
20230 undefined-28.72 M undefined-31.39 M undefined
20220 undefined-51.19 M undefined-51.66 M undefined
20210 undefined-90.32 M undefined-89.95 M undefined
20200 undefined-78.89 M undefined-76.85 M undefined
20190 undefined-39.17 M undefined-36.98 M undefined
20180 undefined-12.12 M undefined-12.48 M undefined
20170 undefined-10.37 M undefined-12.24 M undefined

Quince Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2017201820192020202120222023
0000000
-------
-------
0000000
-10-12-39-78-90-51-28
-------
-12-12-36-76-89-51-31
--200.00111.1117.11-42.70-39.22
26.0126.0119.0329.1829.7233.537.24
-------
Details

Keystats

ⓘ

Revenue and Growth

The Quince Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Quince Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
7.371.799.9133.8106.890.275.06
0000000
0000000
0000000
0.20.96.244.93.62.38
7.572.6106.1137.8111.793.877.44
0.10.31.31.11.40.70.62
0016.850.519.93.60.08
0000000
000005.963.67
00000017.63
0.100.200.208.47
0.20.318.351.621.510.290.46
7.772.9124.4189.4133.2104167.9
             
17.210400000.04
0.10.2185.2318.6355.2389.1401.64
-20.3-32.8-69.8-146.7-236.6-288.3-319.64
000.10.3-0.1-0.33.05
0000000
-371.4115.5172.2118.5100.585.08
0.50.53.13.64.90.62.03
1.215.813.49.32.43.44
0000004.1
0000000
000001000
1.71.58.91714.23.19.57
7.20000013.43
000000.25.3
1.9000.20.4054.51
9.1000.20.40.273.24
10.81.58.917.214.63.382.82
7.872.9124.4189.4133.1103.8167.9
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Quince Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Quince Therapeutics's financial health and stability.

Assets

Quince Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Quince Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Quince Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Quince Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
-12-12-36-76-89-51
000000
000000
00110-4-9
111153017
000000
000000
-9-11-33-50-62-44
000000
0-46-17-525818
0-46-17-525918
000000
700000
0757711860
7757711860
------
000000
-21726152-25
-9.91-11.91-33.34-50.87-63.11-44.17
000000

Quince Therapeutics stock margins

The Quince Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Quince Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Quince Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Quince Therapeutics's sales revenue. A higher gross margin percentage indicates that the Quince Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Quince Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Quince Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Quince Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Quince Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Quince Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Quince Therapeutics Margin History

Quince Therapeutics Gross marginQuince Therapeutics Profit marginQuince Therapeutics EBIT marginQuince Therapeutics Profit margin
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Quince Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Quince Therapeutics earnings per share therefore indicates how much revenue Quince Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Quince Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Quince Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Quince Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Quince Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Quince Therapeutics Revenue, EBIT and net profit per share

DateQuince Therapeutics Sales per ShareQuince Therapeutics EBIT per shareQuince Therapeutics Earnings per Share
20230 undefined-0.77 undefined-0.84 undefined
20220 undefined-1.53 undefined-1.54 undefined
20210 undefined-3.04 undefined-3.03 undefined
20200 undefined-2.7 undefined-2.63 undefined
20190 undefined-2.06 undefined-1.94 undefined
20180 undefined-0.47 undefined-0.48 undefined
20170 undefined-0.4 undefined-0.47 undefined

Quince Therapeutics business model

Cortexyme Inc. is a biotechnology company specializing in the development of therapies for degenerative diseases of the nervous system, particularly Alzheimer's disease. The company was founded in 2012 in South San Francisco by Casey Lynch and Stephen Dominy and has since become a leading company in this field. The origin of Cortexyme stems from the discovery of a new bacteria, Porphyromonas gingivalis (P. gingivalis), made by Lynch, the CEO of Cortexyme. He found that P. gingivalis is present in the vicinity of brain plaques in Alzheimer's patients. This discovery meant that Cortexyme had opportunities to develop prevention and treatment options for degenerative diseases of the nervous system. Cortexyme's business model is based on a combination of R&D (research and development) and precision medicine, enabling them to develop personalized therapy approaches. The company is working to specifically target therapeutic molecules against bacteria associated with Alzheimer's and develop biological solutions that target the bacteria. Cortexyme collaborates with a range of specialists, scientists, and university laboratories to conduct their research. The company also has its own research department focused on the discovery of therapeutics to inhibit or eliminate the growth of P. gingivalis. The company has various divisions focusing on the discovery and development of therapeutics. One division focuses on developing biomarkers to aid the diagnosis of Alzheimer's. Another division is developing targeted antibiotics against P. gingivalis, while a third division focuses on developing therapeutics that inhibit the breakdown of bacteria and plaque in the brain. Cortexyme has also developed several products, including the Alzheimer's drug program Atuzaginstat (COR388), which is currently in Phase III of clinical development. Atuzaginstat aims to inhibit P. gingivalis and has the potential to provide hope to terminally ill Alzheimer's patients. Cortexyme is also working on other products, including COR569 to combat inflammation associated with cognitive decline and COR271 to eliminate bacteria that promote brain inflammation. Overall, Cortexyme has taken a new direction in the exploration of Alzheimer's treatment by investigating the role of bacteria in the disease and developing new therapeutic approaches. The company has positioned itself as a leader in Alzheimer's research and will continue to work on developing innovative therapies and prevention strategies that improve the quality of life for Alzheimer's patients and enhance hope for a cure. Quince Therapeutics is one of the most popular companies on Eulerpool.com.

Quince Therapeutics SWOT Analysis

Strengths

Cortexyme Inc possesses several strengths that contribute to its competitive advantage and growth potential:

  • Strong research and development capabilities, leading to innovative and potentially groundbreaking treatments.
  • A talented team of scientists and researchers with vast expertise in the field.
  • Exclusive access to unique data and discoveries related to the role of Porphyromonas gingivalis in neurodegenerative diseases.
  • Well-established partnerships with reputable academic institutions and industry leaders, fostering collaboration and knowledge exchange.
  • Solid financial position and investor confidence, enabling continued investment in research and development.

Weaknesses

Despite its strengths, Cortexyme Inc faces certain weaknesses that may pose challenges to its success:

  • Relatively small size compared to established pharmaceutical companies, limiting resources and market reach.
  • Dependence on the success of its research and development efforts, posing risks if treatments fail to meet regulatory or commercial expectations.
  • Limited product portfolio, potentially exposing the company to fluctuations in demand and market dynamics.

Opportunities

Cortexyme Inc can leverage various opportunities to maximize its growth potential:

  • Growing awareness and interest in the potential link between gum infections and neurodegenerative diseases, creating a strong market demand.
  • Expanding partnerships with pharmaceutical companies and research institutions for collective research and product development.
  • Advancements in technology and data analytics, enabling more accurate diagnosis, treatment, and personalized medicine.
  • Expanding into international markets to address global unmet needs in neurodegenerative disease treatments.

Threats

Cortexyme Inc faces certain threats that may impact its growth and profitability:

  • Intense competition from large pharmaceutical companies with significant resources and established market presence.
  • Stringent regulatory processes and requirements for drug approval, potentially delaying commercialization efforts.
  • Uncertainty surrounding the acceptance and adoption of new treatments by healthcare professionals and patients.
  • Economic fluctuations and healthcare cost containment measures, impacting affordability and market access.

Quince Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Quince Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Quince Therapeutics shares outstanding

The number of shares was Quince Therapeutics in 2023 — This indicates how many shares 37.237 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Quince Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Quince Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Quince Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Quince Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Quince Therapeutics.

Quince Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
3/31/20240 -0.26  (0 %)2024 Q1
9/30/20230 -0.15  (0 %)2023 Q3
9/30/2022-0.29 -0.22  (24.06 %)2022 Q3
6/30/2022-0.49 -0.51  (-3.09 %)2022 Q2
3/31/2022-0.56 -0.72  (-28.89 %)2022 Q1
12/31/2021-0.66 -0.78  (-17.74 %)2021 Q4
9/30/2021-0.76 -0.73  (3.76 %)2021 Q3
6/30/2021-0.77 -0.74  (4.29 %)2021 Q2
3/31/2021-0.74 -0.78  (-6.02 %)2021 Q1
12/31/2020-0.75 -0.69  (7.62 %)2020 Q4
1
2

Eulerpool ESG Scorecard© for the Quince Therapeutics stock

Eulerpool World ESG Rating (EESG©)

61/ 100

🌱 Environment

65

👫 Social

73

🏛️ Governance

45

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Quince Therapeutics list of shareholders

%
Name
Stocks
Change
Date
8.97334 % Lamond (David A.)3,883,660200,0023/31/2023
7.43993 % Tang Capital Management, LLC3,220,000-278,86812/31/2023
5.83630 % Genextra S.p.A.2,525,9502,525,95011/6/2023
5.03269 % Sofinnova Partners2,178,1502,178,15012/31/2023
2.72777 % Lynch (Casey C)1,180,58003/31/2023
2.24538 % The Vanguard Group, Inc.971,80121,81012/31/2023
2.01047 % EPIQ Capital Group, LLC870,133-56,36712/31/2023
1.59298 % Thye (Dirk)689,441240,5301/16/2024
1.19982 % Low (Philip S)519,28363,9743/31/2023
1.05980 % Renaissance Technologies LLC458,680133,68012/31/2023
1
2
3
4
5
...
10

Quince Therapeutics Executives and Management Board

Dr. Dirk Thye53
Quince Therapeutics Chief Executive Officer, Director (since 2022)
Compensation 4.97 M
Mr. Brendan Hannah38
Quince Therapeutics Chief Operating Officer, Chief Business Officer, Principal Financial Officer and Principal Accounting
Compensation 1.15 M
Ms. June Bray69
Quince Therapeutics Independent Director
Compensation 164,356
Mr. David Lamond48
Quince Therapeutics Independent Chairman of the Board
Compensation 134,186
Dr. Una Ryan81
Quince Therapeutics Lead Independent Director
Compensation 124,436
1
2

Most common questions regarding Quince Therapeutics

What values and corporate philosophy does Quince Therapeutics represent?

Cortexyme Inc represents values and a corporate philosophy focused on innovative research and development in the field of neurodegenerative diseases. The company aims to advance scientific knowledge and discoveries to develop transformative therapies for conditions like Alzheimer's and Parkinson's disease. Cortexyme Inc is committed to improving the lives of patients and approaching neurological disorders with a holistic understanding of the underlying mechanisms. With their dedication to scientific rigor, patient-centered approach, and commitment to delivering novel treatments, Cortexyme Inc is at the forefront of combating neurodegenerative diseases and creating a better future for patients worldwide.

In which countries and regions is Quince Therapeutics primarily present?

Cortexyme Inc is primarily present in the United States.

What significant milestones has the company Quince Therapeutics achieved?

Cortexyme Inc has achieved several significant milestones. The company successfully completed Phase 1 clinical trials for its lead drug candidate, COR388, which showed promising results in targeting a key protein related to Alzheimer's disease. Cortexyme also received Fast Track designation from the U.S. FDA for the development of COR388 in treating Alzheimer's disease. Furthermore, the company raised substantial funding through its initial public offering (IPO) and subsequent stock offerings, enabling them to advance their pipeline of potential therapies. Cortexyme's milestones highlight their dedication to developing innovative treatments for neurodegenerative diseases like Alzheimer's, positioning them as a key player in the healthcare industry.

What is the history and background of the company Quince Therapeutics?

Cortexyme Inc. is a biopharmaceutical company that focuses on developing therapeutics for neurodegenerative diseases. Founded in 2012, Cortexyme is headquartered in South San Francisco, California. The company's mission is to discover and develop disease-modifying therapies to improve the lives of patients with Alzheimer's disease and other aging-related disorders. Cortexyme's innovative approach involves targeting specific pathogenic bacteria that have been found in the brain, aiming to inhibit the production of toxic molecules that contribute to disease progression. With a dedicated team of researchers and partnerships with leading academic institutions, Cortexyme is at the forefront of pioneering treatments for neurodegenerative diseases.

Who are the main competitors of Quince Therapeutics in the market?

The main competitors of Cortexyme Inc in the market include pharmaceutical companies focused on developing treatments for neurodegenerative diseases, such as Biogen Inc, Eli Lilly and Company, and AbbVie Inc. These industry leaders compete with Cortexyme in the development of novel therapies targeting conditions like Alzheimer's disease. Additionally, smaller biotech companies specializing in neurology research and drug discovery may also pose competition to Cortexyme Inc.

In which industries is Quince Therapeutics primarily active?

Cortexyme Inc is primarily active in the biotechnology industry.

What is the business model of Quince Therapeutics?

Cortexyme Inc's business model focuses on the development of therapeutics focusing on the treatment of Alzheimer's disease and other degenerative disorders. The company aims to identify and target specific pathogens that are believed to play a role in the development and progression of these diseases. By exploring the connection between bacterial infections and neurodegenerative conditions, Cortexyme Inc aims to develop innovative drugs to target these underlying causes. Their pharmaceutical research and development team utilize a proprietary drug discovery platform to identify potential drug candidates. Cortexyme Inc aims to bring novel therapies to market that can potentially improve the lives of patients suffering from Alzheimer's disease and related disorders.

What is the P/E ratio of Quince Therapeutics 2024?

The P/E ratio cannot be calculated for Quince Therapeutics at the moment.

What is the P/S ratio of Quince Therapeutics 2024?

The P/S cannot be calculated for Quince Therapeutics currently.

What is the AlleAktien quality score of Quince Therapeutics?

The AlleAktien quality score for Quince Therapeutics is 1/10.

What is the revenue of Quince Therapeutics 2024?

The revenue cannot currently be calculated for Quince Therapeutics.

How high is the profit of Quince Therapeutics 2024?

The profit cannot currently be calculated for Quince Therapeutics.

What is the business model of Quince Therapeutics

Cortexyme Inc is a biotechnology company driven by the discovery of new therapies for neurodegenerative diseases such as Alzheimer's through the use of advanced technologies and innovative research approaches. The company's goal is to identify the underlying causes of neurodegenerative diseases and develop new therapies that target the disease's causes rather than just treating the symptoms. The business model of Cortexyme Inc is based on the research and development of drugs for neurodegenerative diseases. The company has three main divisions: Science and Development, Finance and Marketing, and Regulation and Quality Assurance. In the Science and Development division, the company works to gain new insights into the fundamentals of neurodegenerative diseases and develop innovative therapies based on these insights. The focus is on principles of molecular research, medical technology, and drug development. Cortexyme Inc collaborates closely with leading research institutions worldwide to advance research and develop new technologies to identify the causes of neurodegeneration. The company also utilizes big data analysis and artificial intelligence to generate new insights and accelerate research. One of Cortexyme's key therapeutic areas is the drug CX-525, which targets specific bacterial pathogens with an antibiotic effect that are linked to neurodegenerative diseases (such as Alzheimer's). The drug aims to treat the underlying causes of the disease and thus combat the symptoms. CX-525 was approved by the US Food and Drug Administration (FDA) for clinical trials in 2018. Also in development are the drugs CX-2009 & CX-2029, which target the protein aggregates in the brains of Alzheimer's patients. Cortexyme Inc is also known for its strong support for the patient community. The company works closely with charitable organizations to raise awareness of neurodegenerative diseases and increase understanding of the disease. Through this collaboration, resources can be provided to develop new therapies and help patients and their families make informed treatment choices. Overall, Cortexyme Inc has successfully pursued its goal of developing new research findings and effective therapies against neurodegenerative diseases. The company relies on a combination of innovation, partnership, and industry experience to create better treatment options for patients suffering from these diseases. As a pioneer in the industry, Cortexyme Inc has the potential to make significant advancements towards better healthcare worldwide.

What is the Quince Therapeutics dividend?

Quince Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Quince Therapeutics pay dividends?

The dividend cannot currently be calculated for Quince Therapeutics or the company does not pay out a dividend.

What is the Quince Therapeutics ISIN?

The ISIN of Quince Therapeutics is US22053A1079.

What is the Quince Therapeutics WKN?

The WKN of Quince Therapeutics is A2PHHD.

What is the Quince Therapeutics ticker?

The ticker of Quince Therapeutics is QNCX.

How much dividend does Quince Therapeutics pay?

Over the past 12 months, Quince Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Quince Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Quince Therapeutics?

The current dividend yield of Quince Therapeutics is .

When does Quince Therapeutics pay dividends?

Quince Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Quince Therapeutics?

Quince Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Quince Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Quince Therapeutics located?

Quince Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Quince Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Quince Therapeutics from 9/9/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Quince Therapeutics pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Quince Therapeutics in the year 2023?

In the year 2023, Quince Therapeutics distributed 0 USD as dividends.

In which currency does Quince Therapeutics pay out the dividend?

The dividends of Quince Therapeutics are distributed in USD.

All fundamentals about Quince Therapeutics

Our stock analysis for Quince Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quince Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.